KRAS history

References:

^{1. The Nobel Prize in Physiology or Medicine 1989, The Nobel Assembly at the Karolinska Institute Press Release available at http://nobelprize.org/nobel_prizes/medicine/laureates/1989/press.html}

^{2. Malumbres M, et al. RAS oncogenes: the first 30 years. Nature Reviews Cancer. 2003;3:7-13.}

^{3. Bishop JM. Oncogenes. Scientific American 1982;246:68-78.}

^{4. Bos JL, et al. Prevalence of ras gene mutations in human colorectal cancers. Nature 1987:327;293-7.}

^{5. Lièvre A, et al. KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res 2006:66(8);3992-5.}

^{6. Jonker D, et al. Cetuximab for the treatment of colorectal cancer. N Engl J Med 2007;357:2040-8.}

^{7. DiFiore F, et al. Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by cetuximab plus chemotherapy. Br J Cancer 2007;96:1166-9.}

^{8. Van Cutsem E, et al. Cetuximab and chemotherapy as initial treatment of metastatic colorectal cancer. N Engl J Med 2009;360:1408-17.}

^{9. Tabin CJ, et al. Mechanism of activation of a human oncogene. Nature 1982;300:143-9.}

^{10. Roberts PJ & Der CJ. Ras stories: the state of the art. In: Ras Family GTPases (Proteins and Cell Regulation); Der CJ, ed. Dordrecht, The Netherlands: Springer; 2006. p1-14}